TransThera-B completes on-market buyback of 105,000 H shares, treasury stock rises to 396,000

Bulletin Express07-22 20:03

TransThera Sciences (Nanjing), Inc. (TransThera-B) disclosed that it repurchased 105,000 H shares on 22 July 2026 via the Hong Kong Stock Exchange. The shares were bought at prices ranging from HKD 10.85 to HKD 10.93, representing a volume-weighted average of HKD 10.91 per share and an aggregate consideration of HKD 1.15 million.

Following the transaction: • Issued shares outstanding (excluding treasury shares) decreased to 312.29 million. • Treasury shares increased to 396,000, while total issued shares remained unchanged at 312.69 million. • The repurchased shares are being held as treasury stock; none have been cancelled.

Repurchase mandate status: • Shareholder mandate granted: 18 June 2026. • Authorised shares under mandate: 31.27 million. • Cumulative shares repurchased under mandate: 396,000, equal to 0.13 % of the issued share base at the mandate date. • Moratorium on new share issues or treasury share sales remains in force until 21 August 2026.

Management confirmed that the repurchase was duly authorised by the board, executed in accordance with Hong Kong Main Board rules, and funded with funds already received by the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110558146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110558146","market":"us","top_or_hot":-1,"title":"TransThera-B completes on-market buyback of 105,000 H shares, treasury stock rises to 396,000","media":"Bulletin Express","content":"<p>TransThera Sciences (Nanjing), Inc. (TransThera-B) disclosed that it repurchased 105,000 H shares on 22 July 2026 via the Hong Kong Stock Exchange. The shares were bought at prices ranging from HKD 10.85 to HKD 10.93, representing a volume-weighted average of HKD 10.91 per share and an aggregate consideration of HKD 1.15 million.</p>\n<p>Following the transaction:\n• Issued shares outstanding (excluding treasury shares) decreased to 312.29 million.  \n• Treasury shares increased to 396,000, while total issued shares remained unchanged at 312.69 million.  \n• The repurchased shares are being held as treasury stock; none have been cancelled.</p>\n<p>Repurchase mandate status:\n• Shareholder mandate granted: 18 June 2026.  \n• Authorised shares under mandate: 31.27 million.  \n• Cumulative shares repurchased under mandate: 396,000, equal to 0.13 % of the issued share base at the mandate date.  \n• Moratorium on new share issues or treasury share sales remains in force until 21 August 2026.</p>\n<p>Management confirmed that the repurchase was duly authorised by the board, executed in accordance with Hong Kong Main Board rules, and funded with funds already received by the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera-B completes on-market buyback of 105,000 H shares, treasury stock rises to 396,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera-B completes on-market buyback of 105,000 H shares, treasury stock rises to 396,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-22 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransThera Sciences (Nanjing), Inc. (TransThera-B) disclosed that it repurchased 105,000 H shares on 22 July 2026 via the Hong Kong Stock Exchange. The shares were bought at prices ranging from HKD 10.85 to HKD 10.93, representing a volume-weighted average of HKD 10.91 per share and an aggregate consideration of HKD 1.15 million.</p>\n<p>Following the transaction:\n• Issued shares outstanding (excluding treasury shares) decreased to 312.29 million.  \n• Treasury shares increased to 396,000, while total issued shares remained unchanged at 312.69 million.  \n• The repurchased shares are being held as treasury stock; none have been cancelled.</p>\n<p>Repurchase mandate status:\n• Shareholder mandate granted: 18 June 2026.  \n• Authorised shares under mandate: 31.27 million.  \n• Cumulative shares repurchased under mandate: 396,000, equal to 0.13 % of the issued share base at the mandate date.  \n• Moratorium on new share issues or treasury share sales remains in force until 21 August 2026.</p>\n<p>Management confirmed that the repurchase was duly authorised by the board, executed in accordance with Hong Kong Main Board rules, and funded with funds already received by the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1110558146","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110558146","pubTimestamp":1784721808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TransThera Sciences (Nanjing), Inc. (TransThera-B) disclosed that it repurchased 105,000 H shares on 22 July 2026 via the Hong Kong Stock Exchange. The shares were bought at prices ranging from HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"TransThera-B完成场内回购105,000股H股，库存股增至396,000股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TransThera Sciences (Nanjing), Inc. (TransThera-B) disclosed that it repurchased 105,000 H shares on 22 July 2026 via the Hong Kong Stock Exchange. The shares were bought at prices ranging from HKD 10.85 to HKD 10.93, representing a volume-weighted average of HKD 10.91 per share and an aggregate consideration of HKD 1.15 million.\nFollowing the transaction:\n• Issued shares outstanding (excluding treasury shares) decreased to 312.29 million.  \n• Treasury shares increased to 396,000, while total issued shares remained unchanged at 312.69 million.  \n• The repurchased shares are being held as treasury stock; none have been cancelled.\nRepurchase mandate status:\n• Shareholder mandate granted: 18 June 2026.  \n• Authorised shares under mandate: 31.27 million.  \n• Cumulative shares repurchased under mandate: 396,000, equal to 0.13 % of the issued share base at the mandate date.  \n• Moratorium on new share issues or treasury share sales remains in force until 21 August 2026.\nManagement confirmed that the repurchase was duly authorised by the board, executed in accordance with Hong Kong Main Board rules, and funded with funds already received by the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110558146","isCrawlerRequest":true}